Divergent Clinical Outcomes of the TLPLDC Vaccine in Preventing Melanoma Recurrence and the Impact of the Dendritic Cell Collection Methodology
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer Immunology, Immunotherapy: CII
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
Cancer Immunol. Immunother. 2022 Sep 01;[EPub Ahead of Print], AM Adams, EL Carpenter, GT Clifton, TJ Vreeland, RC Chick, AE O'Shea, PM McCarthy, PM Kemp Bohan, AT Hickerson, FA Valdera, A Tiwari, DF Hale, JR Hyngstrom, AC Berger, JW Jakub, JJ Sussman, MF Shaheen, X Yu, TE Wagner, MB Faries, GE PeoplesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.